


# Contribution of Large-Scale Genomics to Drug Discovery and Development



Vincent Mooser MD, Canada Excellence Research Chair in Genomic Medicine November 18<sup>th</sup>, 2020

## Contribution of Genetics to Drug Discovery and Development



\*ASO: antisense oligonucleotide, SU: sulfonylurea; 5ARI: 5-alpha reductase inhibitor; MPB: Male pattern baldness

FTIM: First time into man; PGX: pharmacogenetics

#### Mission of the CERC

- Contribute to drug discovery and development
- Using genomic medicine


#### **CERC Vision**

- Hub to support primarily target identification, target validation and a new generation of genetically enriched PoC trials
- Capitalize on functional variants, including pLoF
- Capitalize on French-Canadian and cosmopolitan population of Québec


#### **CERC** enabling projects

- The Québec COVID-19 Biobank (BQC19)
- Architecture of coding variants in French-Canadians (FC)
- Development of sequencing technology for CERC needs

## COVID-19 Deaths in Canada (Nov 7th, 2020)



### COVID-19 Hospitalizations in Québec



#### **BQC19 Milestones**

#### Mars 2020

- March 19th, 2020
   : Mandate of the FRQ and Genome Québec
- March 21st, 2020:

   Establishment of the Task Force
   (Steering Committee)
- March 31st, 2020 : Approval by the CHUM Ethics Committee

#### April 2020

 April 1st 2020:
 Recruitment of the 1st patient

June 2020


- June 6th 2020: Recruitment of the 1000th patient
- June 10th 2020: Contract with the Public Health Agency of Canada
- June 15th 2020: Approval of basic analyses by the Governance Committee


**July 2020** 

July 17th 2020:
 Release of first data

## European Settlements in Québec









## French-Canadian exomes are enriched for variants at increased frequency compared to Europeans

